Evidence map›Paper›PMID 30846682›Full record

SynthesisTranslational psychiatry2019

Motor cortex excitability and inhibitory imbalance in autism spectrum disorder assessed with transcranial magnetic stimulation: a systematic review.

Fumi Masuda, Shinichiro Nakajima, Takahiro Miyazaki, Kazunari Yoshida, Sakiko Tsugawa, Masataka Wada, Kamiyu Ogyu, Paul E Croarkin, Daniel M Blumberger, Zafiris J Daskalakis and 2 more

Open access · goldAbstract readSystematic Review
In one paragraph

Synthesis in Translational psychiatry, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers.

0numbers the graph read from it
0cells of the map it votes in
39citing papers in PubMed
4.1field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

39 citing papers in PubMed, 76 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Genetic and pharmacological evidence linking CB1R signaling to hippocampal GABAergic dysfunction in ASD mouse model.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2026
    Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 4 institutions in 3 countries.

Fumi MasudaDepartment of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan.
Shinichiro NakajimaDepartment of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan.
Takahiro MiyazakiDepartment of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan.
Kazunari YoshidaDepartment of Psychiatry and Psychology, Mayo Clinic, Rochester, MN, USA.
Sakiko TsugawaDepartment of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan.
Masataka WadaDepartment of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan.
Kamiyu OgyuDepartment of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan.
Paul E CroarkinPharmacogenetics Research Clinic, Centre for Addiction and Mental Health, Toronto, ON, Canada.
Daniel M BlumbergerTemerty Centre for Therapeutic Brain Intervention, Centre for Addiction and Mental Health and Department of Psychiatry, University of Toronto, Toronto, ON, Canada.
Zafiris J DaskalakisTemerty Centre for Therapeutic Brain Intervention, Centre for Addiction and Mental Health and Department of Psychiatry, University of Toronto, Toronto, ON, Canada.
Masaru MimuraDepartment of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan.
Yoshihiro NodaDepartment of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan. yoshi-tms@keio.jp.ORCID http://orcid.org/0000-0002-2155-0357
Keio University · JPCentre for Addiction and Mental Health · CAMayo Clinic · USShiga University of Medical Science · JP

Funding

Glutamatergic and GABAergic Biomarkers in rTMS for Adolescent DepressionR01MH113700 · NIMH · MAYO CLINIC ROCHESTER · PI CROARKIN, PAUL E · 2017 to 2021
$2.5M
NIMH NIH HHS R01 MH113700
6 · The paper itself

Abstract

Cortical excitation/inhibition (E/I) imbalances contribute to various clinical symptoms observed in autism spectrum disorder (ASD). However, the detailed pathophysiologic underpinning of E/I imbalance remains uncertain. Transcranial magnetic stimulation (TMS) motor-evoked potentials (MEP) are a non-invasive tool for examining cortical inhibition in ASD. Here, we conducted a systematic review on TMS neurophysiology in motor cortex (M1) such as MEPs and short-interval intracortical inhibition (SICI) between individuals with ASD and controls. Out of 538 initial records, we identified six articles. Five studies measured MEP, where four studies measured SICI. There were no differences in MEP amplitudes between the two groups, whereas SICI was likely to be reduced in individuals with ASD compared with controls. Notably, SICI largely reflects GABA(A) receptor-mediated function. Conversely, other magnetic resonance spectroscopy and postmortem methodologies assess GABA levels. The present review demonstrated that there may be neurophysiological deficits in GABA receptor-mediated function in ASD. In conclusion, reduced GABAergic function in the neural circuits could underlie the E/I imbalance in ASD, which may be related to the pathophysiology of clinical symptoms of ASD. Therefore, a novel treatment that targets the neural circuits related to GABA(A) receptor-mediated function in regions involved in the pathophysiology of ASD may be promising.

Indexed as

Neural InhibitionTranscranial Magnetic StimulationAutism Spectrum DisorderEvoked Potentials, Motorgamma-Aminobutyric AcidHumansMotor CortexReceptors, GABA-Agamma-Aminobutyric AcidReceptors, GABA-A

Identifiers

PMID30846682
PMCPMC6405856
OpenAlexW2918320547

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.